Pharmacy selling Ranbaxy drugs again; Judge OKs use of Teva's Plan B; Elan vote referendum on CEO;

@FiercePharma: Catalent kicks off $35M expansion in U.S. More | Follow @FiercePharma

@EricPFierce: Novo suggests overzealous reading of risks of Type 2 diabetes drugs that include Victoza, Januvia. Yesterday's article | Follow @EricPFierce

@CarlyHFierce: Insider trading charges from Sanofi/Chattem deal continue to pile up. Brothers allegedly scored a $50k profit. Report | Follow @CarlyHFierce

> A week after issuing a "cautionary advisory" against drugs made by Ranbaxy Laboratories, leading pharmacy chain Apollo Pharmacy today said it has resolved the matter and will continue to sell the drugmaker's medicines from its outlets across the country. Story

> A U.S. district court judge on Wednesday approved an FDA plan to allow unrestricted sales of Plan B One-Step, a one-pill version of the emergency contraception drug. Story

> The Elan ($ELN) vote is seen as a decision on whether CEO Kelly Martin has the ability to build a company. Story

> The Affordable Care Act may not provide co-pay relief on drugs as soon as expected. Story

Medical Device News

@FierceMedDev: Life Tech buys Korean distributor as Thermo waits. News | Follow @FierceMedDev

@DamianFierce: Venture-backed Natera is expanding its prenatal test as it contends with $SQNM, $ILMN and others. Article | Follow @DamianFierce

@MarkHFierce: Just met in Berlin with Christian Pangratz, CBO of Activaero, which has a promising drug-device liquid inhalation treatment for asthma. | Follow @MarkHFierce

@MichaelGFierce: Chime in on the nano-gold discussion at the FierceBiotech LinkedIn page: Discussion | Follow @MichaelGFierce

> FDA wants tighter cybersecurity for medical devices. More

> Mindray commits $105M to grab U.S. ultrasound imaging company. News

> For heart disease diagnosis, two tests may be better than one. DxExtra

Biotech News

@FierceBiotech: Report: Genomics industry contributed $1 trillion to U.S. economy in last 25 years. Article | Follow @FierceBiotech

 @JohnCFierce: Royalty Pharma scrambles to salvage vote on hostile Elan takeover. Story | Follow @JohnCFierce

@RyanMFierce: GSK has halted a study of an MS compound linked to data fraud in China. The plot thickens. More | Follow @RyanMFierce

 @EmilyMFierce: SCOTUS decision on Myriad case: Natural isolated DNA is not patentable. Synthetic DNA is patentable because it doesn't occur naturally. | Follow @EmilyMFierce

> Japanese biotech Prism snags $15M C round for cancer, fibrosis studies. News

> Lilly's oral rheumatoid arthritis blockbuster contender champions 1-year study. News

> Glaxo's dismissed China R&D chief fires back. Article

Pharma Manufacturing News

> Zydus recalls wafarin after oversized tablets discovered. Item

> FedEx vows not to settle with feds on online pharmacy shipments. Story

> FDA warning letter nails 2 Baxter plants for repeat violations. Article

> FDA comes down on another Indian drugmaker. Report

Vaccines News

> Latin American cancer vax races Big Pharma rivals. More

> FDA clears Sanofi to compete for 4-in-1 flu vaccine market. Report

> FDA setback sends Dynavax shares tumbling again. Article

> Oral vaccine aims to end dreaded Delhi belly. Story

And Finally... There are reasons that most Americans don't want to participate in clinical trials. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.